AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23282124 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80‐320 mg) with awakening dosing
Number of subjects: 60
Study 23282124 — intervention group
Group type: COMPARATOR
Intervention: Patients with dipping BP pattern
Number of subjects: 60
Study 20638877 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine infusion (100‐h, starting at 5 mg/h to 20 mg/h)
Number of subjects: 60
Study 20638877 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 60
Study 19085034 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 20
Study 19085034 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 16716315 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic unilateral tubal fulguration (treatment group, 7 patients)
Number of subjects: 13
Study 16716315 — intervention group
Group type: COMPARATOR
Intervention: No surgical intervention (control group, 6 patients)
Number of subjects: 13
Study 15633319 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + collagen (EMDC)
Number of subjects: 26
Study 15633319 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane (GTRC)
Number of subjects: 26
Study 15633319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (GTRC and EMDC)
Number of subjects: 26
Study 11680558 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐session exposure treatment alone
Number of subjects: 60
Study 11680558 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐session treatment with a parent present
Number of subjects: 60
Study 11680558 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 60
Study 9159367 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer (MT) imaging in HIV-positive patients with PML
Number of subjects: 33
Study 9159367 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer (MT) imaging in HIV-positive patients with HIV encephalitis
Number of subjects: 33
Study 9159367 — intervention group
Group type: COMPARATOR
Intervention: Magnetization transfer (MT) imaging in healthy control subjects
Number of subjects: 33
Study 7971000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (10 mg/kg/day, once daily for 10 days)
Number of subjects: 368
Study 7971000 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (8 mg/kg/day, once daily for 10 days)
Number of subjects: 368
Study 2446077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg orally once or twice daily for 4 weeks)
Number of subjects: 21
Study 30764805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D therapy (800 IU cholecalciferol daily)
Number of subjects: 50
Study 30764805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29133894 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria (MAU)
Number of subjects: 3385
Study 29133894 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria (MAU) in non-pre-diabetic population
Number of subjects: 3385
Study 25209918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical vignette with designated driver program
Number of subjects: 390
Study 25209918 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical vignette without designated driver program
Number of subjects: 390
Study 25209918 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport relying on someone else to drive home
Number of subjects: 390
Study 23911205 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS mixture
Number of subjects: 113
Study 23911205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study 21514808 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation and influenza vaccine
Number of subjects: 2
Study 21514808 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine only
Number of subjects: 2
Study 18543483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Houxue (BSHX) method combined with ultrasound-guided follicle aspiration (MFA)
Number of subjects: 44
Study 18543483 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided follicle aspiration (MFA) alone (Control group)
Number of subjects: 44
Study 17058105 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15-30 mg/day)
Number of subjects: 214
Study 17058105 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 214
Study 15623462 — intervention group
Group type: EXPERIMENTAL
Intervention: DIM (108 mg/day) for 30 days
Number of subjects: 19
Study 15623462 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 19
Study 11398550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) worn for 4-6 weeks
Number of subjects: 28
Study 11398550 — intervention group
Group type: COMPARATOR
Intervention: Maxillary placebo appliance worn for 4-6 weeks
Number of subjects: 28
Study 9269786 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 230
Study 9269786 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 230
Study 9269786 — intervention group
Group type: EXPERIMENTAL
Intervention: S-form PML-RAR alpha mRNA
Number of subjects: 230
Study 9269786 — intervention group
Group type: EXPERIMENTAL
Intervention: S-form vs L-form PML-RAR alpha mRNA
Number of subjects: 230
Study 8489569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-sucralfate association (50 mg)
Number of subjects: 12
Study 8489569 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated tablets (50 mg)
Number of subjects: 12
Study 8489569 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-sucralfate association
Number of subjects: 12
Study 21263970 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone group (notified by telephone)
Number of subjects: 243
Study 21263970 — intervention group
Group type: COMPARATOR
Intervention: Drop-in group (informed during visits)
Number of subjects: 243
Study 28981379 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered, single-session brief motivational intervention plus booster session
Number of subjects: 50
Study 28981379 — intervention group
Group type: EXPERIMENTAL
Intervention: Health checkup for expectant moms (HCEM)
Number of subjects: 50
Study 28981379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27610245 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity consultation and pram walking group intervention
Number of subjects: 0
Study 27610245 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24434886 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 84
Study 24434886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 22115976 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloderm graft
Number of subjects: 20
Study 22115976 — intervention group
Group type: COMPARATOR
Intervention: Mucosal graft
Number of subjects: 20
Study 20048389 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 95
Study 20048389 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 95
Study 18042835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential dose-dense epirubicin 110 mg/m(2) and paclitaxel 250 mg/m(2)
Number of subjects: 1121
Study 18042835 — intervention group
Group type: COMPARATOR
Intervention: Concurrent epirubicin 83 mg/m(2) and paclitaxel 187 mg/m(2)
Number of subjects: 1121
Study 15691532 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 108
Study 15691532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 15691532 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus Fluoxetine (60 mg/day)
Number of subjects: 108
Study 15691532 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus Placebo
Number of subjects: 108
Study 12618901 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent weekly paclitaxel with radiotherapy (group 1)
Number of subjects: 51
Study 12618901 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group 2)
Number of subjects: 51
Study 11299268 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-exercise training program for 20 weeks
Number of subjects: 364
Study 9815842 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐alpha (3 x 10(6) units/m2 for 14 days)
Number of subjects: 15
Study 7948356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric intubation
Number of subjects: 74
Study 7948356 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric intubation
Number of subjects: 74
Study 3285943 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 137
Study 3285943 — intervention group
Group type: COMPARATOR
Intervention: iopromide
Number of subjects: 137
Study 3285943 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol and iopromide
Number of subjects: 137
Study 31615934 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS examination after 3-5 mL submucosal saline injection (SSI)
Number of subjects: 180
Study 31615934 — intervention group
Group type: COMPARATOR
Intervention: EUS only examination
Number of subjects: 180
Study 30031572 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg daily
Number of subjects: 160
Study 30031572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 26755408 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental submaximal cycling exercise
Number of subjects: 27
Study 26755408 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, inactive)
Number of subjects: 27
Study 24256157 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised consumption of methadone or buprenorphine
Number of subjects: 29
Study 24256157 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised consumption of methadone or buprenorphine
Number of subjects: 29
Study 24256157 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised consumption
Number of subjects: 29
Study 24256157 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibly timed discontinuation of supervision
Number of subjects: 29
Study 23582628 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 15 to 30 mg/day
Number of subjects: 224
Study 23582628 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 to 10 mg/day
Number of subjects: 224
Study 20605858 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise training (20-40 minutes of stationary cycling and treadmill exercise, 5 days/week for 4 weeks)
Number of subjects: 22
Study 20605858 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (16 exercises performed with single set, moderate load and high repetitions, 5 days/week for 4 weeks)
Number of subjects: 22
Study 18984840 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (200 mg daily)
Number of subjects: 48
Study 18984840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16616233 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg daily for 12 weeks)
Number of subjects: 13
Study 16616233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16616233 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 13
Study 12783911 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid MRI
Number of subjects: 380
Study 12783911 — intervention group
Group type: COMPARATOR
Intervention: Radiograph
Number of subjects: 380
Study 10971235 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L of cafetière (French press) coffee daily
Number of subjects: 64
Study 10971235 — intervention group
Group type: COMPARATOR
Intervention: No coffee
Number of subjects: 64
Study 8971064 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium treatment (200 microg per day)
Number of subjects: 1312
Study 8971064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1312
Study 1611965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg daily)
Number of subjects: 36
Study 1611965 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100-200 mg daily)
Number of subjects: 36
Study 30661082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spots (DBS)
Number of subjects: 50
Study 28176599 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (oral + topical) tranexamic acid (TXA)
Number of subjects: 100
Study 28176599 — intervention group
Group type: COMPARATOR
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 100
Study 27527817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast injection (2‐4mL/s)
Number of subjects: 120
Study 27527817 — intervention group
Group type: COMPARATOR
Intervention: Slow injection (5‐10mL/s)
Number of subjects: 120
Study 27527817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast injection
Number of subjects: 120
Study 27527817 — intervention group
Group type: COMPARATOR
Intervention: Slow injection
Number of subjects: 120
Study 25105547 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (SEP) plus at home nonsupervised exercise therapy (non‐SET)
Number of subjects: 117
Study 25105547 — intervention group
Group type: COMPARATOR
Intervention: Usual supervised exercise program (SEP) according to a common cardiovascular program
Number of subjects: 117
Study 22357106 — intervention group
Group type: EXPERIMENTAL
Intervention: PINCER intervention (pharmacist-led information technology intervention)
Number of subjects: 480942
Study 22357106 — intervention group
Group type: COMPARATOR
Intervention: Control group (computer-generated simple feedback for at-risk patients)
Number of subjects: 480942
Study 20402818 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, ofloxacin, bismuth, and omeprazole
Number of subjects: 220
Study 20402818 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, clarithromycin, bismuth, and omeprazole
Number of subjects: 220
Study 17854748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 15791634 — intervention group
Group type: COMPARATOR
Intervention: Sarizotan (5-HT1A agonist) at 2 and 5 mg twice daily
Number of subjects: 18
Study 11978899 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 300 mg/kg over 20 h
Number of subjects: 30
Study 11978899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11978899 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 30
Study 9856380 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 100
Study 9856380 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medication
Number of subjects: 100
Study 7824707 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 41
Study 7824707 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE
Number of subjects: 41
Study 2162281 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate of 50 l/min
Number of subjects: 11
Study 2162281 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate of 150 l/min
Number of subjects: 11
Study 374707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut toothbrush bristles (CP)
Number of subjects: 30
Study 374707 — intervention group
Group type: COMPARATOR
Intervention: Round ended toothbrush bristles (RP)
Number of subjects: 30
Study 30610423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV) implantation
Number of subjects: 23
Study 30610423 — intervention group
Group type: COMPARATOR
Intervention: Suprachoroidal silicone tube (SST) implantation
Number of subjects: 23
Study 26149677 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation condition
Number of subjects: 63
Study 26149677 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 63
Study 26073411 — intervention group
Group type: EXPERIMENTAL
Intervention: Part D plan switching
Number of subjects: 185960
Study 26073411 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting switching
Number of subjects: 185960
Study 23584194 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 288
Study 23584194 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education
Number of subjects: 288
Study 23584194 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline abstinence
Number of subjects: 288
Study 23584194 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with someone with an alcohol problem
Number of subjects: 288
Study 23584194 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent interpersonal trauma at baseline and higher total of lifetime trauma exposures
Number of subjects: 288
Study 21672347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion)
Number of subjects: 64
Study 21672347 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 64
Study 19801246 — intervention group
Group type: EXPERIMENTAL
Intervention: K-files (group 1)
Number of subjects: 36
Study 19801246 — intervention group
Group type: EXPERIMENTAL
Intervention: M-Two NiTi rotary instruments (group 2)
Number of subjects: 36
Study 19801246 — intervention group
Group type: EXPERIMENTAL
Intervention: ESI ultrasonic tips (group 3)
Number of subjects: 36
Study 19801246 — intervention group
Group type: COMPARATOR
Intervention: Thermafil
Number of subjects: 36
Study 19801246 — intervention group
Group type: COMPARATOR
Intervention: Vertically compacted warm gutta-percha
Number of subjects: 36
Study 19801246 — intervention group
Group type: COMPARATOR
Intervention: Coronal third (control)
Number of subjects: 36
Study 19801246 — intervention group
Group type: COMPARATOR
Intervention: Middle third
Number of subjects: 36
Study 19801246 — intervention group
Group type: COMPARATOR
Intervention: Apical third
Number of subjects: 36
Study 17083585 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid (PLLA) injections
Number of subjects: 0
Study 15580192 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of stationary cycling
Number of subjects: 25
Study 15580192 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 25
Study 11423702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of 68 g olive and 12 g sunflower oil/day (MO; total 80 g)
Number of subjects: 28
Study 11423702 — intervention group
Group type: COMPARATOR
Intervention: 80 g corn oil (CO)/day
Number of subjects: 28
Study 9268794 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA) with various techniques (semiconstrained, with/without posterior cruciate ligament retention, resurfacing of the patella, cement fixation)
Number of subjects: 55
Study 9268794 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group (32 knees in 32 patients without TKA)
Number of subjects: 55
Study 8329907 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia given before surgery (group 1)
Number of subjects: 0
Study 8329907 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia given after surgery (group 2)
Number of subjects: 0
Study 3333523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 18
Study 3333523 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 160 mg slow release once daily
Number of subjects: 18
Study 3333523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29724529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified yogurt (FY) - 2 servings (2 x 250 g)/day
Number of subjects: 87
Study 29724529 — intervention group
Group type: COMPARATOR
Intervention: Low-fat plain yogurt (PY) - control group
Number of subjects: 87
Study 28480650 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB + BMS
Number of subjects: 180
Study 28480650 — intervention group
Group type: COMPARATOR
Intervention: ZES
Number of subjects: 180
Study 26651471 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based physical activity intervention
Number of subjects: 55
Study 26651471 — intervention group
Group type: COMPARATOR
Intervention: Active control arm
Number of subjects: 55
Study 24004498 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alcohol screening and brief intervention (e‐SBI)
Number of subjects: 772
Study 24004498 — intervention group
Group type: COMPARATOR
Intervention: Screening alone (control)
Number of subjects: 772
Study 24004498 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐SBI
Number of subjects: 772
Study 20978709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment (75 mg/day) with MEA assessment
Number of subjects: 31
Study 20978709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment (75 mg/day) with LTA assessment
Number of subjects: 31
Study 18316662 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms measured with the Center for Epidemiological Studies Depression Scale
Number of subjects: 269
Study 18316662 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 269
Study 18316662 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 269
Study 16974167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear liquid diet/magnesium citrate and bisacodyl prep
Number of subjects: 114
Study 16974167 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet kit/magnesium citrate and bisacodyl prep
Number of subjects: 114
Study 16974167 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet kit/polyethylene glycol electrolyte prep
Number of subjects: 114
Study 16974167 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 114
Study 14579086 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (AD)
Number of subjects: 42
Study 14579086 — intervention group
Group type: COMPARATOR
Intervention: Group II (MCI)
Number of subjects: 42
Study 14579086 — intervention group
Group type: EXPERIMENTAL
Intervention: Left prefrontal, left frontal and left parietal areas
Number of subjects: 42
Study 14579086 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial temporal and anterior lateral temporal cortex
Number of subjects: 42